<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00722124</url>
  </required_header>
  <id_info>
    <org_study_id>07-006365</org_study_id>
    <secondary_id>07-006604</secondary_id>
    <nct_id>NCT00722124</nct_id>
  </id_info>
  <brief_title>S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence</brief_title>
  <official_title>S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmavite</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cigarette smoking is of great public health importance and is the single most important
      preventable cause of morbidity, mortality and excess health care costs in the United States.
      After a steady decline for the last 50 years, the prevalence of tobacco use in the United
      States has reached a plateau of approximately 21%. Currently available treatments among
      adults are not efficacious for all tobacco users. New pharmacologic agents thus need to be
      continually developed and tested.

      The release of dopamine in the nucleus accumbens is one of the key components of the
      pleasurable and rewarding effects of nicotine. Drugs that increase monoamine neurotransmitter
      availability (particularly dopamine and norepinephrine) are likely to increase the reward
      function and thus ameliorate withdrawal symptoms. S-Adenosyl-L-Methionine (SAMe), the primary
      methyl donor for the central nervous system (CNS), donates methyl groups towards presynaptic
      synthesis of CNS monoamine neurotransmitters. By facilitating the synthesis of dopamine and
      norepinephrine in the brain, SAMe is likely to ameliorate the symptoms of nicotine
      withdrawal, thus improving tobacco abstinence rates in smokers who are trying to stop
      smoking. SAMe is well tolerated and is available over-the-counter.

      To date, no prospective clinical trial evaluating the efficacy of SAMe for the treatment of
      tobacco dependence has been published. We propose to evaluate the efficacy of SAMe for
      increasing smoking abstinence and decreasing nicotine withdrawal symptoms in a randomized,
      blinded, placebo-controlled, three-arm, parallel-group, dose-ranging phase II clinical trial.
      Participants (N=120) will be randomly assigned to one of the three groups, and will receive
      an 8-week course of SAMe 800-mg per day, 1600-mg per day, or a matching placebo. This study
      is anticipated to provide the data needed to develop a larger randomized controlled clinical
      trial submitted through the R01 funding mechanism, if the results appear promising.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, after consenting, subject is screened for study eligibility. If they pass the
      study screen, they are randomized to study drug (800 mg/day of SAMe, 1600 mg/day of SAMe or
      placebo-look-alike). Subjects will stay on their assigned dose for 8 weeks with weekly
      (visits 3-6) or biweekly (visits 7-8) clinic visits. After the 8 weeks of medication, they
      will receive a phone visit at week 16 and then a final visit at week 24. Study participation
      ends at the week 24 visit. During study participation, subjects will undergo counseling at
      every study visit based on the counseling manual, Smoke Free and Living It. They will also
      keep diaries (record of daily withdraw symptoms and tobacco use) for the 8 weeks while on
      study medication. At each study visit, smoking and safety outcomes are measured.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>7-day Point Prevalence Smoking Abstinence at End of Treatment (Week 8)</measure>
    <time_frame>8 weeks</time_frame>
    <description>7-day point prevalence smoking abstinence biochemically confirmed (expired carbon monoxide &lt;8ppm)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Tobacco Dependence</condition>
  <arm_group>
    <arm_group_label>SAMe 800</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject randomized to this arm will take a 400 mg pill of SAMe and one matching placebo pill in the AM and again in the PM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAMe 1600</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each person randomized to this arm will take 2 400 mg pills of SAMe in the AM and again in the PM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each subject randomized to this arm will take 2 placebo pills in the AM and again in the PM</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-Adenosyl-L-Methionine</intervention_name>
    <description>800 mg dose per day for 8 weeks</description>
    <arm_group_label>SAMe 800</arm_group_label>
    <other_name>SAMe</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-Adenosyl-L-Methionine</intervention_name>
    <description>1600 mg per day for 8 weeks</description>
    <arm_group_label>SAMe 1600</arm_group_label>
    <other_name>SAMe</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>4 pills (2 in the AM and 2 in the PM) of placebos for 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is at least 18 years of age;

          -  Has smoked more than 10 cigarettes/day for â‰¥6 months;

          -  Is willing to make a quit attempt;

          -  Is able to participate fully in all aspects of the study;

          -  Has been provided with, understand, and have signed the informed consent.

          -  Is in good health as determined by the physician investigator.

        Exclusion Criteria:

          -  Is clinically significant levels of current depression as assessed by CESD (Score &gt;16)
             and determined by the physician; or have a life-time diagnosis of bipolar disorder,
             schizophrenia or dementia as determined by physician investigator;

          -  Has an unstable medical condition.

          -  Is using other tobacco product and the primary use is NOT cigarettes.

          -  Is currently (within the past 30-days) using antipsychotics or antidepressants;

          -  Is currently (within the past 30-days) using any treatments for tobacco dependence
             (i.e., behavioral therapy, nicotine replacement therapy, bupropion SR, clonidine, or
             nortriptyline);

          -  Is currently using another investigational drug at the time of study enrollment;

          -  Is currently (within the past 30 days) using an herbal product or dietary supplement
             for tobacco abstinence;

          -  Has recent history (in the past 3-months) of alcohol abuse or dependence as assessed
             by the CAGE questionnaire and study investigators;

          -  Has a recent history of drug abuse as assessed by physician interview;

          -  Is pregnant, lactating, or of child bearing potential, likely to become pregnant
             during the medication phase and not willing to use a reliable form of contraception.
             Reliable forms of contraception include diaphragm or condom (with spermicidal),
             injections, intrauterine device [IUD], surgical sterilization and abstinence;

          -  Is a history of any major cardiovascular events in the past 3-months including
             unstable angina, acute MI or coronary angioplasty;

          -  Has clinically significant acute or chronic progressive or unstable neurologic,
             hepatic, renal, cardiovascular, respiratory or metabolic disease;

          -  Is currently on medications interacting with SAMe, including but not limited to,
             antidepressants, MAO inhibitors, levodopa, meperidine, dextromethorphan, pentazocine
             and tramadol;

          -  Has another household member or relative participating in the study;

          -  Has known allergy to SAMe.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit Sood, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan Skemp HealthCare</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2008</study_first_submitted>
  <study_first_submitted_qc>July 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2008</study_first_posted>
  <results_first_submitted>August 5, 2011</results_first_submitted>
  <results_first_submitted_qc>August 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 9, 2011</results_first_posted>
  <last_update_submitted>August 5, 2011</last_update_submitted>
  <last_update_submitted_qc>August 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Amit Sood, M.D.</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>tobacco use</keyword>
  <keyword>cigarettes</keyword>
  <keyword>smokers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment began on 10/07/08 and completed on 10/01/09. Interested subjects who passed a phone pre-screen were seen at a medical clinic (Mayo Clinic in Rochester, MN and Franciscan Skemp Medical Center in Lacrosse, WI) for consenting and additional study procedures to determine eligibility.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>SAMe 800</title>
          <description>Each subject randomized to this arm will take a 400 mg pill of SAMe and one matching placebo pill in the AM and again in the PM</description>
        </group>
        <group group_id="P2">
          <title>SAMe 1600</title>
          <description>Each person randomized to this arm will take 2 400 mg pills of SAMe in the AM and again in the PM</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Each subject randomized to this arm will take 2 placebo pills in the AM and again in the PM</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SAMe 800</title>
          <description>Each subject randomized to this arm will take a 400 mg pill of SAMe and one matching placebo pill in the AM and again in the PM</description>
        </group>
        <group group_id="B2">
          <title>SAMe 1600</title>
          <description>Each person randomized to this arm will take 2 400 mg pills of SAMe in the AM and again in the PM</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Each subject randomized to this arm will take 2 placebo pills in the AM and again in the PM</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.1" spread="16.0"/>
                    <measurement group_id="B2" value="40.8" spread="12.3"/>
                    <measurement group_id="B3" value="37.0" spread="13.6"/>
                    <measurement group_id="B4" value="39.9" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>baseline smoking rate</title>
          <description>Average cigarettes per day at study entry</description>
          <units>cigarettes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.5" spread="9.3"/>
                    <measurement group_id="B2" value="19.9" spread="8.4"/>
                    <measurement group_id="B3" value="19.5" spread="8.0"/>
                    <measurement group_id="B4" value="19.6" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>7-day Point Prevalence Smoking Abstinence at End of Treatment (Week 8)</title>
        <description>7-day point prevalence smoking abstinence biochemically confirmed (expired carbon monoxide &lt;8ppm)</description>
        <time_frame>8 weeks</time_frame>
        <population>Analysis was performed using intention to treat(ITT). Subjects who discontinued study participation were assumed to be smoking.</population>
        <group_list>
          <group group_id="O1">
            <title>SAMe 800</title>
          </group>
          <group group_id="O2">
            <title>SAMe 1600</title>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>7-day Point Prevalence Smoking Abstinence at End of Treatment (Week 8)</title>
          <description>7-day point prevalence smoking abstinence biochemically confirmed (expired carbon monoxide &lt;8ppm)</description>
          <population>Analysis was performed using intention to treat(ITT). Subjects who discontinued study participation were assumed to be smoking.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Data were compared between treatment groups using Fisher's Exact test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.615</p_value>
            <method>Fisher Exact</method>
            <method_desc>1 sided</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Data were compared between treatment groups using Fisher's Exact test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.826</p_value>
            <method>Fisher Exact</method>
            <method_desc>1 sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>SAMe 800</title>
          <description>Each subject randomized to this arm will take a 400 mg pill of SAMe and one matching placebo pill in the AM and again in the PM</description>
        </group>
        <group group_id="E2">
          <title>SAMe 1600</title>
          <description>Each person randomized to this arm will take 2 400 mg pills of SAMe in the AM and again in the PM</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Each subject randomized to this arm will take 2 placebo pills in the AM and again in the PM</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>heartburn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>drowsiness/fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>vivid dreams</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amit Sood, MD</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266-1944</phone>
      <email>nicotineresearch@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

